Frequently Asked Questions about Erasca, Inc. (ERAS)

Name: Erasca, Inc. (ERAS) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Erasca, Inc. (ERAS) do?

Accepted Answer

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, ...

Question 2

Is Erasca, Inc. (ERAS) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ERAS reveals an Altman Z-Score of 41.83 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if ERAS fits their risk profile.

Question 3

What is the current P/E ratio for ERAS?

Accepted Answer

As of the latest trading session, Erasca, Inc. (ERAS) has a trailing P/E ratio of -37.54.

Question 4

Who is the CEO of Erasca, Inc.?

Accepted Answer

The current Chief Executive Officer of Erasca, Inc. is Jonathan E. Lim.

Question 5

What was ERAS's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Erasca, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does ERAS pay a dividend?

Accepted Answer

Erasca, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ERAS have?

Accepted Answer

In its latest reporting period, Erasca, Inc. generated $-0.10B in Free Cash Flow against a total debt load of $0.05B.

Question 8

What is the Price-to-Book (P/B) ratio of Erasca, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Erasca, Inc. (ERAS) is currently 14.38.

Question 9

What is the Price-to-Sales (P/S) ratio of ERAS?

Accepted Answer

Based on trailing twelve-month data, Erasca, Inc. (ERAS) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Erasca, Inc.'s Return on Equity (ROE)?

Accepted Answer

Erasca, Inc. (ERAS) has a Return on Equity (ROE) of -34.48%, representing its profitability relative to shareholder equity.